Compositions and Methods for the Treatment of Herpes Simplex Virus Infections

DESCRIPTION
Herpes simplex viruses (HSV) are the causative agent for a variety of diseases, yet there are very few effective anti-HSV agents on the market. There is no vaccine and no cure for HSV. Currently available treatment options, which include intravenous infusion of antiviral agents, often result in serious side effects such as kidney failure. Moreover, relapse of the disease is common with such therapeutic approaches.

This technology describes the application of pooled human immunoglobulin for the prevention and treatment of the breadth of HSV-related diseases including encephalitis, pneumonia, hepatitis, herpes ocularis, keratitis, herpes digitalis, herpes facialis, herpes genitalis, herpes gladiatorum, or herpes stomatitis.

KEY ASPECTS
- Novel approach for prevention and treatment of wide array of HSV-related diseases
- Powerful efficacy to control HSV infection
- Avoids dangerous side effects associated with currently available antiviral treatments on the market
- Can be administered alone or in combination with other anti-HSV agents

INTELLECTUAL PROPERTY

<table>
<thead>
<tr>
<th>Title</th>
<th>US Application Number</th>
<th>Filed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compositions and Methods for Treating Herpes Simplex Virus Infections and Related Diseases</td>
<td>12/482,418</td>
<td>6/10/2009</td>
</tr>
</tbody>
</table>

CONTACT
Ryan Kelly, Ph.D.
Manager, Office of Technology Licensing
Telephone: (626) 471 9359 | Email: rykelly@coh.org

This material is a summary of public domain and non-confidential City of Hope information. Additional material may be disclosed under a confidentiality agreement.

MK-008